Central venous catheters play a major role in modern healthcare. These catheters allow easy administration of intravenous fluids, blood products, medications, and parenteral nutrition, as well as offer hemodialysis access and hemodynamic monitoring. They are used in various diseases for longer duration therapies such as cancer (chemotherapy) and end stage renal disease (dialysis).
U.S. Central Venous Catheter Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector, which has been majorly impacted by the pandemic. COVID-19 has also affected the economies in three main ways- by directly affecting the production and demand, by creating disruptions in distribution channels, and through its financial impact on companies and financial markets. The increase in central-line–associated bloodstream infections and blood culture contamination rates increase the market growth. For instance, in November 2020, National Center for Biotechnology Information published a report which reported that a there was a significant increase in central-line–associated bloodstream infections and blood culture contamination rates during the pandemic. Blood culture contamination rates were 19% higher during the COVID-19 period, whereas the CLABSI (central-line–associated bloodstream infections) rate during the pandemic increased by 25% in US.
Thus, impact of the Coronavirus (COVID-19) pandemic had driven the growth of the U.S. central venous catheter market during the pandemic.
U.S. central venous catheter market is estimated to be valued at US$ 1,023.41 million in 2022 and is expected to exhibit a CAGR of 6.2% during the forecast period (2022-2030).
Figure 1: U.S. Central Venous Catheter Market Share, (%), Analysis, By Design, 2022
Increasing number of advantages associated with single lumen is expected to drive the growth of U.S. central venous catheter market
Increasing advantages associated with single lumen drives the growth of U.S. central venous catheter market over the forecast period. For example:
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 1,023.41 Mn |
| Historical Data for: | 2018 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 6.2% | 2030 Value Projection: | US$ 1,657.13 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
AngioDynamics, Inc, C.R. Bard, Inc, Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc, Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc.,ICU Medical, Inc.,Theragenics Corporation, Becton, Dickinson and Company,icumedical, Polymedicure, Lepu Medical Technology (Beijing) Co.,Ltd., VOGT MEDICAL, Gilead Sciences, Inc and ZOLL Medical Corporation |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
U.S. Central Venous Catheter Market – Restraints
There are various restrains associated with central venous catheter market such as:
Figure 2: U.S. Central Venous Catheter Market Value (US$ Mn), By Product Type, 2022
Increasing use of peripherally inserted central catheters is expected to bolster the U.S. central venous catheter market growth over the forecast period.
Increasing use of peripherally inserted central catheters associated with low complications is expected to drive the growth of U.S. central venous catheter market over the forecast period. For instance, in May 2021, Journal of Medicine and Life, a peer-reviewed open access journal, published a report which stated that PICCs (peripherally inserted central catheters) may be used as a safe option for central venous access in children either in the intermediate- or long-term. New types of PICC may facilitate broader indications and provide longer dwell times. PICC placement can be learned easily, usually requires light sedation and/or local anesthesia, and seldom causes serious perioperative risks. Application of assisted visualization and having well-educated staff could improve the insertion success rate and reduce the complications of PICCs.
U.S. Central Venous Catheter Market - Competitive Landscape
Key players operating in the global osteoporosis drugs market include AngioDynamics, Inc, C.R. Bard, Inc, Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc, Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc.,ICU Medical, Inc.,Theragenics Corporation, Becton, Dickinson and Company,icumedical, Polymedicure, Lepu Medical Technology (Beijing) Co.,Ltd., VOGT MEDICAL, Gilead Sciences, Inc and ZOLL Medical Corporation
A central venous catheter (KATHeter), also known as a central line or CVC, is a long, soft, thin, hollow tube that is placed into a large vein (blood vessel). A central venous catheter differs from an intravenous (IV) catheter placed in the hand or arm (also called a “peripheral IV”). A central line is longer, with a larger tube, and is placed in a large (central) vein in the neck, upper chest or groin. This type of catheter has special benefits in that it can deliver fluids into a larger vein, and that it can stay in the body for a longer period of time than a usual, shorter IV.
Common reasons for having a central line include:
Market Dynamics
The research and development of device like central venous catheter by the market player is expected to drive the growth of U.S. central venous catheter market over the forecast period. For instance, in May 2018, Pursuit Vascular Inc., a medical device company, announced that the US Food and Drug Administration (FDA) had granted clearance for a broader indication for ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infections (CLABSI) in hemodialysis patients with central venous catheters (CVCs).
Moreover, increasing prevalence of cardiovascular disease in the U.S. is expected to drive the growth of U.S. central venous catheter market over the forecast period. For instance, in January 2021, Heart Disease and Strokes Statistics, the U.S. age-adjusted death rate attributable to cardiovascular disease (CVD), based on 2018 data, on average, someone dies of CVD every 36 seconds. There are 2,380 deaths from CVD each day, based on 2018 data, whereas someone dies of a stroke every 3 minutes and 33 seconds in the U.S. There are about 405 deaths from stroke each day, based on 2018 data.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients